Background and objective Patient-reported outcome measures can provide clinicians with valuable information to improve doctor-patient communication and inform clinical decision-making. The aim of this study was to evaluate the physician-perceived utility of the QLQ-GINET21 in routine clinical practice in patients with gastrointestinal neuroendocrine tumours (GI-NETs). Secondary aims were to explore the patient, clinician, and/or centre-related variables potentially associated with perceived clinical utility. Methods Non-interventional, cross-sectional, multicentre study conducted at 34 hospitals in Spain and Portugal (NCT02853422). Patients diagnosed with GI-NETs completed two health-related quality of life (HRQoL) questionnaires (QLQ-...
There are clinical situations (CS) in which the use of somatostatin analogs (SSAs) in patients with ...
AIM: To combine and test the EORTC questionnaires for assessing quality of life (HRQL) for oesophage...
Background: Assessment of clinical benefit of systemic treatments of rare diseases including gastroe...
Background and objective Patient-reported outcome measures can provide clinicians with valuable inf...
Patient-reported outcome measures can provide clinicians with valuable information to improve doctor...
Background:Quality of life is an important end point in clinical trials, yet there are few quality o...
Among the available neuroendocrine neoplasm (NEN)-specific HR-QoL scales, only the EORTC QLQ-C30 and...
Among the available neuroendocrine neoplasm (NEN)-specific HR-QoL scales, only the EORTC QLQ-C30 and...
Quality of life (QoL) measurements are increasingly being used as an end point in cancer clinical tr...
questionnaire for assessing quality of life of patients with gastrointestinal neuroendocrine tumour
Spanish Neuroendocrine Tumor Group (GETNE)© 2015, Springer Science+Business Media New York. Gastroen...
Abstract Background Gastroenteropancreatic neuroendocrine tumours (GEP-NETs) are rare cancers most o...
Context: Although health-related quality of life (HRQoL) is a fundamental outcome in oncological cli...
OBJECTIVE: To evaluate the impact of multidisciplinary team (MDT) meetings on the management of pati...
The genomic era has introduced concepts of “personalized medicine” and “targeted therapy” in the fie...
There are clinical situations (CS) in which the use of somatostatin analogs (SSAs) in patients with ...
AIM: To combine and test the EORTC questionnaires for assessing quality of life (HRQL) for oesophage...
Background: Assessment of clinical benefit of systemic treatments of rare diseases including gastroe...
Background and objective Patient-reported outcome measures can provide clinicians with valuable inf...
Patient-reported outcome measures can provide clinicians with valuable information to improve doctor...
Background:Quality of life is an important end point in clinical trials, yet there are few quality o...
Among the available neuroendocrine neoplasm (NEN)-specific HR-QoL scales, only the EORTC QLQ-C30 and...
Among the available neuroendocrine neoplasm (NEN)-specific HR-QoL scales, only the EORTC QLQ-C30 and...
Quality of life (QoL) measurements are increasingly being used as an end point in cancer clinical tr...
questionnaire for assessing quality of life of patients with gastrointestinal neuroendocrine tumour
Spanish Neuroendocrine Tumor Group (GETNE)© 2015, Springer Science+Business Media New York. Gastroen...
Abstract Background Gastroenteropancreatic neuroendocrine tumours (GEP-NETs) are rare cancers most o...
Context: Although health-related quality of life (HRQoL) is a fundamental outcome in oncological cli...
OBJECTIVE: To evaluate the impact of multidisciplinary team (MDT) meetings on the management of pati...
The genomic era has introduced concepts of “personalized medicine” and “targeted therapy” in the fie...
There are clinical situations (CS) in which the use of somatostatin analogs (SSAs) in patients with ...
AIM: To combine and test the EORTC questionnaires for assessing quality of life (HRQL) for oesophage...
Background: Assessment of clinical benefit of systemic treatments of rare diseases including gastroe...